Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanism

Cancer Immunology Research

Volumn 4, Issue 3, 2016, Pages 183-193

  Sundström, Patrik ^a   Stenstad, Hanna ^a   Langenes, Veronica ^a   Ahlmanner, Filip ^a   Theander, Lisa ^a   Ndah, Tapuka Gordon ^a   Fredin, Kamilla ^a   Börjesson, Lars ^b   Gustavsson, Bengt ^b   Bastid, Jeremy ^c   Quiding Järbrink, Marianne ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c OREGA Biotech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; APYRASE; LEUKOCYTE ANTIGEN;

ARTICLE; CANCER PATIENT; CELL MIGRATION; CLINICAL ARTICLE; COLON CANCER; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; MONOCYTE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; ADENOCARCINOMA; CELL CULTURE; COCULTURE; COLON TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOCARCINOMA; ADENOSINE; ANTIGENS, CD; APYRASE; CELLS, CULTURED; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; T-LYMPHOCYTES, REGULATORY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84962018445     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0050     Document Type: Article

References (51)

1. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
3. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
4. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67.
5. Raghavan S, Quiding-Jarbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2011;5:489-501.
6. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol 2008;38:901-37.
7. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-5.
8. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204:1303-10.
9. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32.
10. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65.
11. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
12. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High frequency of tumor-infiltrating FOXP3 (+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010;126:2635-43.
13. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33:435-41.
14. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006;1:e129.
15. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigenspecific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009;119:3311-21.
16. Brudvik KW, Henjum K, Aandahl EM, Bjornbeth BA, Tasken K. Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother 2012;61:1045-53.
17. + CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur J Immunol 2007;37:282-91.
18. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol 2006;177:6780-6.
19. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009;30:102-8.
20. + regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009;183:7602-10.
21. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348-57.
22. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997;90:1600-10.
23. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414:916-20.
24. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumorT cells. Proc Natl Acad Sci U S A 2006;103:13132-7.
25. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, etal. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003;101:3985-90.
26. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008;111:251-9.
27. + regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol 2009;123:1287-96 e2.
28. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996;270:C522-9.
29. Umapathy NS, Fan Z, Zemskov EA, Alieva IB, Black SM, Verin AD. Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. Vascul Pharmacol 2010;52:199-206.
30. Takedachi M, Qu D, Ebisuno Y, Oohara H, Joachims ML, McGee ST, et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol 2008;180:6288-96.
31. + CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005;73:523-31.
32. Enarsson K, Brisslert M, Backert S, Quiding-Jarbrink M. Helicobacter pylori induces trans endothelial migration of activated memory T cells. Infect Immun 2005;73:761-9.
33. Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015;3:254-65.
34. Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, et al. Highly prevalent colorectal cancer-infiltrating LAP (+) Foxp3 (-) T cells exhibit more potent immunosuppressive activity than Foxp3 (+) regulatory T cells. Mucosal Immunol 2014;7:428-39.
35. Grunewald JK, Ridley AJ. CD73 represses pro-inflammatory responses in human endothelial cells. J Inflamm 2010;7:10.
36. Wagsater D, Dienus O, Lofgren S, Hugander A, Dimberg J. Quantification of the chemokines CCL17 and CCL22 in human colorectal adenocarcinomas. Mol Med Report 2008;1:211-7.
37. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6inhuman malignancywith focusoncolorectal cancer. Int J Cancer 2009;125:741-5.
38. Mandapathil M, Szczepanski M, Harasymczuk M, Ren J, Cheng D, Jackson EK, et al. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4 (+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunol 2012;1:659-69.
39. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68.
40. Hashimoto K, Kataoka N, Nakamura E, Hagihara K, Hatano M, Okamoto T, et al. Monocyte trans-endothelial migration augments subsequent transmigratory activity with increased PECAM-1 and decreased VE-cadherin at endothelial junctions. Int J Cardiol 2011;149:232-9.
41. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772-9.
42. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491:254-8.
43. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011;60:909-18.
44. Zhang H, Conrad DM, Butler JJ, Zhao C, Blay J, Hoskin DW. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3', 5'-monophosphate and phosphatases. J Immunol 2004;173:932-44.
45. Ethier MF, Chander V, Dobson JG Jr. Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol 1993;265:H131-8.
46. Barcz E, Sommer E, Sokolnicka I, Gawrychowski K, Roszkowska-Purska K, Janik P, et al. The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells. Oncol Rep 1998;5:517-20.
47. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010;139:1030-40.
48. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol 2012;106:130-7.
49. Maurer CA, Friess H, Kretschmann B, Wildi S, Muller C, Graber H, et al. Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 1998;79:76-81.
50. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008;205:2125-38.
51. Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, et al. Immunological mechanisms oftheantitumor effectsofsupplemental oxygenation. Science Transl Med 2015;7:277ra30.